Citations 1
European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis.
Vannucchi, Alessandro M. , Mascarenhas, John , Bose, Prithviraj , Gale, Robert Peter , Harrison, Claire , Hehlmann, Rüdiger , Koschmieder, Steffen , Tefferi, Ayalew , Barbui, Tiziano , Vannucchi, Alessandro M , Mascarenhas, John , Gale, Robert P , Bose, Prithviraj , Koschmieder, Steffen , Marchetti, Monia , Álvarez‐Larrán, Alberto , Hehlmann, Rűdiger, Kiladjian, Jean‐Jacques , Mesa, Ruben A. , Passamonti, Francesco , Rambaldi, Alessandro
No container title available | June 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available
Abstract Most myelofibrosis (MF) drug approvals by Health Authorities are based on 1 or 2 outcome measures such as spleen volume reduction and/or improved quality-of-life. This 1–2 dimensional approach fails to capture the clinical complexity of MF. A European LeukemiaNet (ELN) taskforce developed a composite endpoint which allows multiple outcomes to be simultaneously measured. The panel used the Desirability-Of-Outcome-Ranking (DOOR) method to assign 25 outcomes into 4 quartiles based on a multi-dimensional desirability score and build a 5-layer composite outcome named Desirability-of-Myelofibrosis-Outcomes (DEMYO). Outcome operational definitions were tested by Delphi consensus and correlations with survival validated by a literature review. The outcomes assigned to the first two quartiles were negatively correlated with leukemia-free survival and survival. DEMYO comprehensively captures relevant MF clinical features and meaningful endpoints. Despite DEMYO requires validation based on available trial data, it is expected to improve the quality of Health Authority approvals for new drugs for MF.